- Home
- ALX vs SDGR Comparison
ALX vs SDGR Comparison
Compare ALX & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- SDGR
- Stock Information
- Founded
- ALX 1928
- SDGR 1990
- Country
- ALX United States
- SDGR United States
- Employees
- ALX N/A
- SDGR N/A
- Industry
- ALX Real Estate Investment Trusts
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- SDGR Health Care
- Exchange
- ALX Nasdaq
- SDGR Nasdaq
- Market Cap
- ALX 1.2B
- SDGR 1.4B
- IPO Year
- ALX N/A
- SDGR 2020
- Fundamental
- Price
- ALX $232.14
- SDGR $19.74
- Analyst Decision
- ALX
- SDGR Buy
- Analyst Count
- ALX 0
- SDGR 8
- Target Price
- ALX N/A
- SDGR $26.75
- AVG Volume (30 Days)
- ALX 85.3K
- SDGR 1.1M
- Earning Date
- ALX 11-03-2025
- SDGR 11-11-2025
- Dividend Yield
- ALX 7.75%
- SDGR N/A
- EPS Growth
- ALX N/A
- SDGR N/A
- EPS
- ALX 7.28
- SDGR N/A
- Revenue
- ALX $218,089,000.00
- SDGR $237,917,000.00
- Revenue This Year
- ALX N/A
- SDGR $22.73
- Revenue Next Year
- ALX N/A
- SDGR $19.85
- P/E Ratio
- ALX $31.44
- SDGR N/A
- Revenue Growth
- ALX N/A
- SDGR 18.59
- 52 Week Low
- ALX $184.76
- SDGR $16.60
- 52 Week High
- ALX $260.84
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- ALX 46.29
- SDGR 48.61
- Support Level
- ALX $230.08
- SDGR $19.10
- Resistance Level
- ALX $243.60
- SDGR $22.03
- Average True Range (ATR)
- ALX 6.54
- SDGR 1.03
- MACD
- ALX -0.64
- SDGR -0.04
- Stochastic Oscillator
- ALX 13.10
- SDGR 36.35
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.